Get started
Author

Jelena Urosevic

Genetic analysis of Ras signalling pathways in cell proliferation, migration and survival
2010 · Matthias Drosten, Alma Dhawahir, et al. · The EMBO Journal · 347
MSK1 regulates luminal cell differentiation and metastatic dormancy in ER+ breast cancer
2018 · Sylwia Gawrzak, Lorenzo Rinaldi, et al. · Nature Cell Biology · 130
Constitutive activation of B-Raf in the mouse germ line provides a model for human cardio-facio-cutaneous syndrome
2011 · Jelena Urosevic, Vincent Sauzeau, et al. · Proceedings of the National Academy of Sciences · 72
PDF
The Next-Generation Oral Selective Estrogen Receptor Degrader Camizestrant (AZD9833) Suppresses ER+ Breast Cancer Growth and Overcomes Endocrine and CDK4/6 Inhibitor Resistance
2023 · Mandy Lawson, Natalie Cureton, et al. · Cancer Research · 70
PDF
VEGF pathway inhibition potentiates PARP inhibitor efficacy in ovarian cancer independent of BRCA status
2021 · Francesca Bizzaro, Ilaria Fuso Nerini, et al. · Journal of Hematology & Oncology · 61
PDF
Stratification and therapeutic potential of PML in metastatic breast cancer
2016 · Natalia Martín-Martín, Marco Piva, et al. · Nature Communications · 57
PDF
The landscape of therapeutic vulnerabilities in EGFR inhibitor osimertinib drug tolerant persister cells
2022 · Steven W. Criscione, Matthew J. Martin, et al. · npj Precision Oncology · 56
PDF
Osimertinib, an Irreversible Next-Generation EGFR Tyrosine Kinase Inhibitor, Exerts Antitumor Activity in Various Preclinical NSCLC Models Harboring the Uncommon EGFR Mutations G719X or L861Q or S768I
2020 · Nicolas Floc'h, Sangbin Lim, et al. · Molecular Cancer Therapeutics · 50
Targeting BCL2 Overcomes Resistance and Augments Response to Aurora Kinase B Inhibition by AZD2811 in Small Cell Lung Cancer
2023 · Kavya Ramkumar, Azusa Tanimoto, et al. · Clinical Cancer Research · 32
PDF
Discovery and In Vivo Efficacy of AZ-PRMT5i-1, a Novel PRMT5 Inhibitor with High MTA Cooperativity
2024 · James M. Smith, Bernard Barlaam, et al. · Journal of Medicinal Chemistry · 25
BID expression determines the apoptotic fate of cancer cells after abrogation of the spindle assembly checkpoint by AURKB or TTK inhibitors
2023 · Jordi Bertran-Alamillo, Ana Giménez-Capitán, et al. · Molecular Cancer · 21
PDF
Quantitative evaluation of trastuzumab deruxtecan pharmacokinetics and pharmacodynamics in mouse models of varying degrees of HER2 expression
2024 · Christina Vasalou, Theresa A. Proia, et al. · CPT Pharmacometrics & Systems Pharmacology · 19
PDF
Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical models
2023 · Lorna Hopcroft, Eleanor M. Wigmore, et al. · npj Breast Cancer · 19
PDF
Aurora B inhibitors promote RB hypophosphorylation and senescence independent of p53-dependent CDK2/4 inhibition
2024 · Shivam Vora, Ariel Andrew, et al. · Cell Death and Disease · 15
PDF
Severe central nervous system thrombotic events in hemoglobin Sabine patient
2003 · Sonja Pavlovic, Milos Kuzmanovic, et al. · European Journal Of Haematology · 15
Aurora B inhibition induces hyper-polyploidy and loss of long-term proliferative potential in RB and p53 defective cells
2025 · Shivam Vora, Saptarshi Chatterjee, et al. · Cell Death and Disease · 10
PDF
Differential ABC transporter expression during hematopoiesis contributes to neutrophil-biased toxicity of Aurora kinase inhibitors
2022 · David B. Chou, Brooke A. Furlong, et al. · Nature Communications · 8
PDF
Erratum: The metabolic co-regulator PGC1α suppresses prostate cancer metastasis
2017 · Veronica Torrano, Lorea Valcarcel-Jimenez, et al. · Nature Cell Biology · 8
PDF
Using cells devoid of RAS proteins as tools for drug discovery
2009 · Jelena Urosevic, Eleanor Y.M. Sum, et al. · Molecular Carcinogenesis · 8
Abstract 6272: AZ-PRMT5i-1: A potent MTAP-selective PRMT5 inhibitor with pharmacodynamic and monotherapy anti-tumor activity in MTAP-deleted tumours
2023 · James T. Lynch, Shaun Moore, et al. · Cancer Research · 6
Epigenetic Silencing of MTAP in Hodgkin's Lymphoma Renders It Sensitive to a 2 nd Generation PRMT5 Inhibitor
2023 · Jelena Urosevic, James T. Lynch, et al. · Blood · 5
PRIMAVERA: A Modular Phase I/II Study to Evaluate the Safety, Tolerability, and Efficacy of AZD3470, a Protein Arginine Methyltransferase 5 (PRMT5) Inhibitor, in Participants with Relapsed/Refractory Hematologic Malignancies
2024 · Tae Min Kim, Katharine L. Lewis, et al. · Blood · 4
PDF
Abstract LB008: Integrative dynamic MultiOMICs analysis identifies cell cycle and DNA damage response phenotypes as downstream consequences of using the PRMT5 inhibitor AZD3470
2024 · Ted Hong, Steven Criscione, et al. · Cancer Research · 4
Use of Human Dose Prediction Metrics to Enable Discovery of AZD3470, an MTA-Cooperative PRMT5 Inhibitor in Clinical Evaluation
2026 · James M. Smith, Bernard Barlaam, et al. · Journal of Medicinal Chemistry · 2
146 (PB134): First disclosure of AZD3470, a highly potent MTA-cooperative PRMT5 inhibitor in PRIMROSE and PRIMAVERA clinical studies
2024 · J. Smith, J. Urosevic, et al. · European Journal of Cancer · 2
Works count: 123
Citation count: 1,057
H-index: 15
I10-index: 16
Year
Topic
Type